patent/TW-200730531-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-200730531-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-06
filingDate	2006-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90eb34717b862b43ce538e001965ed9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0604ec24a080ec43b0a78c0e17bac6e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c31bdd459a9721671bdac1e38eda917d
publicationDate	2007-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	TW-200730531-A
titleOfInvention	7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amine
abstract	The compound having the structural formula I, or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease. Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
priorityDate	2005-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16038400 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410202846

Total number of triples: 30.